Compare EXLS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXLS | CRNX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | 2004 | 2018 |
| Metric | EXLS | CRNX |
|---|---|---|
| Price | $28.19 | $83.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $46.80 | ★ $76.75 |
| AVG Volume (30 Days) | 2.6M | ★ 6.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $12.61 | $720.10 |
| Revenue Next Year | $10.55 | $184.67 |
| P/E Ratio | $66.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.85 | $25.83 |
| 52 Week High | $47.08 | $84.00 |
| Indicator | EXLS | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 92.91 |
| Support Level | $26.88 | $41.42 |
| Resistance Level | $31.06 | N/A |
| Average True Range (ATR) | 0.97 | 0.85 |
| MACD | 0.27 | 2.82 |
| Stochastic Oscillator | 79.15 | 99.68 |
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.